Table 3: Efficacy and long-term outcome of ESDa for
ECGb in different indications.
|
|
Fan et al. (2021) [17] |
Probst et al. (2017) [28] |
||||
|
|
AI c |
EI d |
BEI e |
AI c |
EI d |
BEI e |
|
Follow-up period Median (mo.) |
58.1 |
|
51 |
56 |
36 |
|
|
No. of patients |
265 |
137 |
93 |
53 |
84 |
27 |
|
En bloc resection. % |
100.0 |
100.0 |
93.0 |
98.4 |
89.0 |
89.7 |
|
Curative resection. % |
98.5 |
97.8 |
0 |
90.2 |
73.6 |
0 |
|
Local recurrence % |
0.4 |
0 |
0 |
0 |
4.8 |
11.1 |
|
Metastatic recurrence % |
2.5 |
0.8 |
0 |
0 |
1.2 |
11.1 |
|
Metachronous lesion % |
0.4 |
0 |
2.3 |
15.1 |
7.1 |
7.4 |
aESD:
Endoscopic Submucosal Dissection; bECG: Early Gastric Cancer; cAI:
Absolute Indication; dEI: Expanded Indication; eBEI:
Beyond the Expanded Indication.